Chinghai Kao - Publications

Affiliations: 
Microbiology & Immunology Indiana University, Bloomington, Bloomington, IN, United States 
Area:
Immunology, Oncology

46 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Raikwar SP, Kao CH, Gardner TA. Targeted Adenoviral Vectors III: Transcriptional Targeting Adenoviral Vectors For Gene Therapy: Second Edition. 259-292. DOI: 10.1016/B978-0-12-800276-6.00010-3  0.32
2011 Steding CE, Wu ST, Zhang Y, Jeng MH, Elzey BD, Kao C. The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology. 133: 221-38. PMID 21453419 DOI: 10.1111/j.1365-2567.2011.03429.x  0.32
2011 Li Y, Sikes RA, Malaeb BS, Yeung F, Law A, Graham SE, Pei M, Kao C, Nelson J, Koeneman KS, Chung LW. Osteoblasts can stimulate prostate cancer growth and transcriptionally down-regulate PSA expression in cell line models. Urologic Oncology. 29: 802-8. PMID 20451417 DOI: 10.1016/j.urolonc.2009.09.016  0.32
2010 Jiménez JA, Li X, Zhang YP, Bae KH, Mohammadi Y, Pandya P, Kao C, Gardner TA. Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL Cancer Gene Therapy. 17: 180-191. PMID 19798123 DOI: 10.1038/cgt.2009.62  0.32
2009 Ahn M, Lee SJ, Li X, Jiménez JA, Zhang YP, Bae KH, Mohammadi Y, Kao C, Gardner TA. Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter Cancer Gene Therapy. 16: 73-82. PMID 18772902 DOI: 10.1038/cgt.2008.59  0.32
2008 Mellon MJ, Bae KH, Steding CE, Jiménez JA, Kao C, Gardner TA. Suppression of renal cell carcinoma growth and metastasis with sustained antiangiogenic gene therapy. Human Gene Therapy. 19: 487-95. PMID 18507514 DOI: 10.1089/hum.2007.135  0.32
2008 Li X, Liu YH, Lee SJ, Gardner TA, Jeng MH, Kao C. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 291-9. PMID 18172281 DOI: 10.1158/1078-0432.CCR-07-0867  0.32
2008 Mellon MJ, Ahn M, Jiménez JA, Kao C, Gardner TA. Anti-angiogenic gene therapy for metastatic renal cell carcinoma produces tumor growth suppression in an athymic nude mouse model. The Journal of Urology. 179: 737-42. PMID 18082201 DOI: 10.1016/j.juro.2007.09.017  0.32
2007 Shirakawa T, Terao S, Hinata N, Tanaka K, Takenaka A, Hara I, Sugimura K, Matsuo M, Hamada K, Fuji K, Okegawa T, Higashihara E, Gardner TA, Kao C, Chung LW, et al. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Human Gene Therapy. 18: 1225-32. PMID 18021019 DOI: 10.1089/hum.2007.074  0.32
2007 Li X, Liu YH, Zhang YP, Zhang S, Pu X, Gardner TA, Jeng MH, Kao C. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5463-73. PMID 17875776 DOI: 10.1158/1078-0432.CCR-07-0342  0.32
2007 Abbosh PH, Li X, Li L, Gardner TA, Kao C, Nephew KP. A conditionally replicative, Wnt/beta-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. Cancer Gene Therapy. 14: 399-408. PMID 17218945 DOI: 10.1038/sj.cgt.7701024  0.32
2006 Jiménez JA, Kao C, Raikwar S, Gardner TA. Current status of anti-angiogenesis therapy for prostate cancer. Urologic Oncology. 24: 260-8. PMID 16678061 DOI: 10.1016/j.urolonc.2005.11.022  0.32
2006 Desai P, Jiménez JA, Kao C, Gardner TA. Future innovations in treating advanced prostate cancer. The Urologic Clinics of North America. 33: 247-72, viii. PMID 16631463 DOI: 10.1016/j.ucl.2005.12.005  0.32
2006 Li X, Jung C, Liu YH, Bae KH, Zhang YP, Zhang HJ, Vanderputten D, Jeng MH, Gardner TA, Kao C. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis. The Journal of Gene Medicine. 8: 679-89. PMID 16570242 DOI: 10.1002/jgm.904  0.32
2006 Li X, Raikwar SP, Liu YH, Lee SJ, Zhang YP, Zhang S, Cheng L, Lee SD, Juliar BE, Gardner TA, Jeng MH, Kao C. Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene. Molecular Cancer Therapeutics. 5: 676-84. PMID 16546982 DOI: 10.1158/1535-7163.MCT-05-0339  0.32
2005 Li X, Zhang J, Gao H, Vieth E, Bae KH, Zhang YP, Lee SJ, Raikwar S, Gardner TA, Hutchins GD, VanderPutten D, Kao C, Jeng MH. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter. Molecular Cancer Therapeutics. 4: 1850-9. PMID 16373700 DOI: 10.1158/1535-7163.MCT-05-0167  0.32
2005 Raikwar SP, Temm CJ, Raikwar NS, Kao C, Molitoris BA, Gardner TA. Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 1091-100. PMID 16169279 DOI: 10.1016/j.ymthe.2005.07.690  0.32
2005 Jung C, Kim RS, Zhang H, Lee SJ, Sheng H, Loehrer PJ, Gardner TA, Jeng MH, Kao C. HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. British Journal of Cancer. 92: 2233-9. PMID 15928669 DOI: 10.1038/sj.bjc.6602631  0.32
2005 Li X, Zhang YP, Kim HS, Bae KH, Stantz KM, Lee SJ, Jung C, Jiménez JA, Gardner TA, Jeng MH, Kao C. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer Research. 65: 1941-51. PMID 15753394 DOI: 10.1158/0008-5472.CAN-04-3666  0.32
2005 Jiménez JA, Kao C, Lee SJ, Jung C, Gardner TA. Gene therapy for prostate cancer Prostate Cancer: Basic Mechanisms and Therapeutic Approaches. 75-105. DOI: 10.1142/9789812569202_0004  0.32
2004 Lee SJ, Zhang Y, Lee SD, Jung C, Li X, Kim HS, Bae KH, Jeng MH, Kao C, Gardner T. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 1051-8. PMID 15564137 DOI: 10.1016/j.ymthe.2004.08.028  0.32
2004 Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA, Eble JN. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Research. 24: 2135-40. PMID 15330153  0.32
2004 Hong H, Kao C, Jeng MH, Eble JN, Koch MO, Gardner TA, Zhang S, Li L, Pan CX, Hu Z, MacLennan GT, Cheng L. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer. 101: 83-9. PMID 15221992 DOI: 10.1002/cncr.20327  0.32
2004 Lim HY, Ahn M, Chung HC, Gardner TA, Kao C, Lee SJ, Kim SJ. Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus. Cancer Gene Therapy. 11: 532-8. PMID 15167900 DOI: 10.1038/sj.cgt.7700732  0.32
2004 Zheng QH, Gardner TA, Raikwar S, Kao C, Stone KL, Martinez TD, Mock BH, Fei X, Wang JQ, Hutchins GD. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorganic & Medicinal Chemistry. 12: 2887-93. PMID 15142549 DOI: 10.1016/j.bmc.2004.03.051  0.32
2004 Shirakawa T, Gotoh A, Zhang Z, Kao C, Chung LW, Gardner TA. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer. Urology. 63: 613-8. PMID 15028478 DOI: 10.1016/j.urology.2003.09.054  0.32
2004 Cheng L, MacLennan GT, Pan CX, Jones TD, Moore CR, Zhang S, Gu J, Patel NB, Kao C, Gardner TA. Allelic loss of the active X chromosome during bladder carcinogenesis. Archives of Pathology & Laboratory Medicine. 128: 187-90. PMID 14736285 DOI: 10.1043/1543-2165(2004)128<187:ALOTAX>2.0.CO;2  0.32
2004 Wang JQ, Zheng QH, Fei X, Liu X, Gardner TA, Kao C, Raikwar SP, Glick-Wilson BE, Sullivan ML, Mock BH, Hutchins GD. An Improved Total Synthesis of PET HSV-tk Gene Expression Imaging Agent 9-[(3-[18F]Fluoro-1-hydroxy-2-propoxy)methyl]guanine ([ 18F]FHPG) Synthetic Communications. 34: 917-932. DOI: 10.1081/SCC-120028365  0.32
2004 Zheng QH, Wang JQ, Liu X, Fei X, Mock BH, Glick-Wilson BE, Sullivan ML, Raikwar SP, Gardner TA, Kao C, Hutchins GD. An Improved Total Synthesis of PET HSV-tk Gene Reporter Probe 9-(4-[ 18F]Fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG) Synthetic Communications. 34: 689-704. DOI: 10.1081/SCC-120027717  0.32
2003 Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. The American Journal of Pathology. 163: 2271-6. PMID 14633601 DOI: 10.1016/S0002-9440(10)63584-5  0.32
2003 Li X, Cui Q, Kao C, Wang GJ, Balian G. Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone. 33: 652-9. PMID 14555271 DOI: 10.1016/S8756-3282(03)00239-4  0.32
2003 Li JZ, Hankins GR, Kao C, Li H, Kammauff J, Helm GA. Osteogenesis in rats induced by a novel recombinant helper-dependent bone morphogenetic protein-9 (BMP-9) adenovirus. The Journal of Gene Medicine. 5: 748-56. PMID 12950065 DOI: 10.1002/jgm.412  0.32
2003 Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, Kao C, Lim SD, Amin MB, Yang H, Black ME, Matsubara S, Nakagawa M, Gillenwater JY, Zhau HE, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Human Gene Therapy. 14: 227-41. PMID 12639303 DOI: 10.1089/10430340360535788  0.32
2002 Gardner TA, Sloan J, Raikwar SP, Kao C. Prostate cancer gene therapy: past experiences and future promise. Cancer Metastasis Reviews. 21: 137-45. PMID 12465753 DOI: 10.1023/A:1020875925685  0.32
2002 Lee SJ, Kim HS, Yu R, Lee K, Gardner TA, Jung C, Jeng MH, Yeung F, Cheng L, Kao C. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Molecular Therapy : the Journal of the American Society of Gene Therapy. 6: 415-21. PMID 12231179 DOI: 10.1006/mthe.2002.0682  0.32
2002 Zhang S, Zeng G, Kao C, Gardner T, Sweeney C, Yang NS, Eble JN, Cheng L. Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system. The Prostate. 53: 69-76. PMID 12210482 DOI: 10.1002/pros.10132  0.32
2002 Jiang J, Ulbright TM, Zhang S, Eckert GJ, Kao C, Gardner TA, Koch MO, Eble JN, Cheng L. Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Cancer. 95: 296-300. PMID 12124829 DOI: 10.1002/cncr.10674  0.32
2002 Cheon J, Moon DG, Cho HY, Park HS, Kim JJ, Gardner TA, Kao C. Adenovirus-mediated suicide-gene therapy in an orthotopic murine bladder tumor model. International Journal of Urology : Official Journal of the Japanese Urological Association. 9: 261-7. PMID 12060439 DOI: 10.1046/j.1442-2042.2002.00464.x  0.32
2002 Zhang S, Gu J, Yang NS, Kao C, Gardner TA, Eble JN, Cheng L. Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer. The Prostate. 51: 286-92. PMID 11987157 DOI: 10.1002/pros.10081  0.32
2001 Shirakawa T, Sasaki R, Gardner TA, Kao C, Zhang ZJ, Sugimura K, Matsuo M, Kamidono S, Gotoh A. Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells International Journal of Cancer. 94: 282-289. PMID 11668510 DOI: 10.1002/ijc.1453  0.32
2000 Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko SC, Kao C, Gardner TA, Chung LWK. Tissue-specific promoters in gene therapy for the treatment of prostate cancer Molecular Urology. 4: 73-82. PMID 12006246 DOI: 10.1089/10915360050138620  0.32
2000 Shirakawa T, Gotoh A, Gardner TA, Kao C, Zhang ZJ, Matsubara S, Wada Y, Hinata N, Fujisawa M, Hanioka K, Matsuo M, Kamidono S. P53 Adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model Journal of Gene Medicine. 2: 426-432. PMID 11199263 DOI: 10.1002/1521-2254(200011/12)2:6<426::AID-JGM140>3.0.CO;2-2  0.32
2000 Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF, Gillenwater JY, Zhau HE, Cluing LWK, Gardner TA. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis World Journal of Urology. 18: 102-110. PMID 10854144 DOI: 10.1007/s003450050181  0.32
1999 Shirakawa T, Gardner TA, Ko SC, Bander N, Woo S, Gotoh A, Kamidono S, Chung LWK, Kao C. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5- fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model Journal of Urology. 162: 949-954. PMID 10458414 DOI: 10.1097/00005392-199909010-00096  0.32
1998 Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. The Journal of Urology. 160: 220-9. PMID 9628654 DOI: 10.1016/S0022-5347(01)63094-5  0.32
1992 Schiller JH, Bittner G, Oberley TD, Kao C, Harris C, Meisner LF. Establishment and characterization of a SV40 T-antigen immortalized human bronchial epithelial cell line. In Vitro Cellular & Developmental Biology : Journal of the Tissue Culture Association. 28: 461-4. PMID 1522038 DOI: 10.1007/BF02634125  0.32
Show low-probability matches.